(Q37954583)

25 August 2017

title

Prognostic implications of genetic aberrations in acute myelogenous leukemia with normal cytogenetics (English)

1 reference

25 August 2017

1 reference

Hady Ghanem

1

1 reference

25 August 2017

Niki Tank

series ordinal

2

1 reference

25 August 2017

Imad A Tabbara

series ordinal

3

1 reference

25 August 2017

language of work or name

1 reference

10 November 2011

1 reference

American Journal of Hematology

25 August 2017

published in

1 reference

25 August 2017

volume

87

1 reference

25 August 2017

issue

1

1 reference

25 August 2017

page(s)

69-77

1 reference

Cytogenetics in acute leukemia

25 August 2017

cites work

1 reference

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

21 January 2018

1 reference

The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial

21 January 2018

1 reference

Age and acute myeloid leukemia

21 January 2018

1 reference

Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial

21 January 2018

1 reference

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations

21 January 2018

1 reference

Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype

21 January 2018

1 reference

Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances

21 January 2018

1 reference

Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).

21 January 2018

1 reference

CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations

21 January 2018

1 reference

Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study

21 January 2018

1 reference

Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics

21 January 2018

1 reference

The clinical significance of karyotype in acute myelogenous leukemia.

21 January 2018

1 reference

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia

21 January 2018

1 reference

Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1.

21 January 2018

1 reference

Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study

21 January 2018

1 reference

A pilot study of high-throughput, sequence-based mutational profiling of primary human acute myeloid leukemia cell genomes.

21 January 2018

1 reference

Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias

21 January 2018

1 reference

21 January 2018

Nucleophosmin and cancer

1 reference

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype

21 January 2018

1 reference

Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B.

21 January 2018

1 reference

Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features

21 January 2018

1 reference

Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study

21 January 2018

1 reference

The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia

21 January 2018

1 reference

A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial

21 January 2018

1 reference

Nucleophosmin acts as a novel AP2alpha-binding transcriptional corepressor during cell differentiation

21 January 2018

1 reference

Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia

21 January 2018

1 reference

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

21 January 2018

1 reference

Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation

21 January 2018

1 reference

FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations

21 January 2018

1 reference

The role of FLT3 in haematopoietic malignancies

21 January 2018

1 reference

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

21 January 2018

1 reference

Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.

21 January 2018

1 reference

Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16).

21 January 2018

1 reference

Internal tandem duplications of Flt3 gene (Flt3/ITD) predicts a poor post-remission outcome in adult patients with acute non-promyelocytic leukemia.

21 January 2018

1 reference

Risk assessment in patients with acute myeloid leukemia and a normal karyotype

21 January 2018

1 reference

Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia

21 January 2018

1 reference

Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome.

21 January 2018

1 reference

No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials.

21 January 2018

1 reference

Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN-AML) and FLT3ITD.

21 January 2018

1 reference

Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis

21 January 2018

1 reference

Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia

21 January 2018

1 reference

Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML.

21 January 2018

1 reference

Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome

21 January 2018

1 reference

Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.

21 January 2018

1 reference

Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study

21 January 2018

1 reference

A clinical overview of WT1 gene mutations

21 January 2018

1 reference

The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis

21 January 2018

1 reference

Genetics of myeloid leukemias

21 January 2018

1 reference

Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party

21 January 2018

1 reference

Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study

21 January 2018

1 reference

WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system.

21 January 2018

1 reference

Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia

21 January 2018

1 reference

Implications of NRAS mutations in AML: a study of 2502 patients

21 January 2018

1 reference

RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years

21 January 2018

1 reference

Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study

21 January 2018

1 reference

Role of NADP+-dependent isocitrate dehydrogenase (NADP+-ICDH) on cellular defence against oxidative injury by gamma-rays

21 January 2018

1 reference

Recurring mutations found by sequencing an acute myeloid leukemia genome

21 January 2018

1 reference

Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation.

21 January 2018

1 reference

Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor

21 January 2018

1 reference

Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study

21 January 2018

1 reference

IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status

21 January 2018

1 reference

IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

21 January 2018

1 reference

Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group

21 January 2018

1 reference

IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication

21 January 2018

1 reference

Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value

21 January 2018

1 reference

The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status

21 January 2018

1 reference

Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia

21 January 2018

1 reference

The prognostic significance of IDH2 mutations in AML depends on the location of the mutation

21 January 2018

1 reference

Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1.

21 January 2018

1 reference

DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome

21 January 2018

1 reference

DNMT3A Mutations in Acute Myeloid Leukemia

21 January 2018

1 reference

Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia

21 January 2018

1 reference

Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML.

21 January 2018

1 reference

Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission.

21 January 2018

1 reference

TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study

21 January 2018

1 reference

TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics

21 January 2018

1 reference

BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications

21 January 2018

1 reference

BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study

21 January 2018

1 reference

High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CAL

21 January 2018

1 reference

BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

21 January 2018

1 reference

BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML).

21 January 2018

1 reference

A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG

21 January 2018

1 reference

ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays

21 January 2018

1 reference

The MN1 oncoprotein synergizes with coactivators RAC3 and p300 in RAR-RXR-mediated transcription.

21 January 2018

1 reference

The 1,25(OH)2D3-regulated transcription factor MN1 stimulates vitamin D receptor-mediated transcription and inhibits osteoblastic cell proliferation.

21 January 2018

1 reference

High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics

21 January 2018

1 reference

Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study

21 January 2018

1 reference

MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML.

21 January 2018

1 reference

Elevated expression of the AF1q gene, an MLL fusion partner, is an independent adverse prognostic factor in pediatric acute myeloid leukemia

21 January 2018

1 reference

Increased AF1q gene expression in high-risk myelodysplastic syndrome.

21 January 2018

1 reference

Elevated AF1q expression is a poor prognostic marker for adult acute myeloid leukemia patients with normal cytogenetics

21 January 2018

1 reference

Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines

21 January 2018

1 reference

EVI1 induces myelodysplastic syndrome in mice

21 January 2018

1 reference

High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients

21 January 2018

1 reference

High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated.

21 January 2018

1 reference

Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia

21 January 2018

1 reference

The protein Id: a negative regulator of helix-loop-helix DNA binding proteins

21 January 2018

1 reference

Id-1 as a molecular target in therapy for breast cancer cell invasion and metastasis

21 January 2018

1 reference

Overexpression of Id-1 is associated with poor clinical outcome in node negative breast cancer

21 January 2018

1 reference

High Id1 expression is associated with poor prognosis in 237 patients with acute myeloid leukemia.

21 January 2018

1 reference

Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells

21 January 2018

1 reference

The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia.

21 January 2018

1 reference

Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129.

21 January 2018

1 reference

Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias

21 January 2018

1 reference

Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.

21 January 2018

1 reference

Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group

21 January 2018

1 reference

Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation.

21 January 2018

1 reference

Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.

21 January 2018

1 reference

Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease.

21 January 2018

1 reference

Sensitive measurement of quantity dynamics of FLT3 internal tandem duplication at early time points provides prognostic information

21 January 2018

1 reference

Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibit

21 January 2018

1 reference

Integrative prognostic risk score in acute myeloid leukemia with normal karyotype

21 January 2018

1 reference

Disclosure of Candidate Genes in Acute Myeloid Leukemia With Complex Karyotypes Using Microarray-Based Molecular Characterization

21 January 2018

1 reference

Frequency and Heritability ofWT1Mutations in Nonsyndromic Wilms' Tumor Patients: A UK Children’s Cancer Study Group Study

21 January 2018

1 reference

Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1)

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/AJH.22197

1 reference

25 August 2017

1 reference